Lv31
270 积分 2024-10-17 加入
The risk of malignancy in patients with secukinumab‐treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow‐up
21天前
已完结
Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis
21天前
已完结
Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature
22天前
已完结
Infection and infestation-related adverse events of biologics in psoriasis: insights from the food and drug administration adverse event reporting system (FAERS)
1个月前
已完结
Post-Marketing Safety Surveillance of Adalimumab, Secukinumab, and Infliximab in Hidradenitis Suppurativa: An Analysis of the FDA Adverse Events Reporting System (FAERS) Database
1个月前
已关闭
Infection and infestation-related adverse events of biologics in psoriasis: insights from the food and drug administration adverse event reporting system (FAERS)
1个月前
已完结
Novel anti-psoriasis agent-associated cardiotoxicity, analysis of the FDA adverse event reporting system (FAERS)
1个月前
已完结
Short-term risk and long-term incidence rate of infection and malignancy with IL-17 and IL-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis
1个月前
已完结
Efficacy and safety of IL-17 inhibitors for the treatment of ankylosing spondylitis: a systematic review and meta-analysis
1个月前
已完结
Effects of secukinumab and ixekizumab on major adverse cardiovascular events in patients with psoriasis: a meta-analysis of randomized controlled trials
1个月前
已完结
皖公网安备34019202002308
